A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Phase of Trial: Phase III
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PROSPECT
- Sponsors Bavarian Nordic; BN ImmunoTherapeutics
- 14 Sep 2017 According to a Bavarian Nordic media release, an independent Data Monitoring Committee (DMCB) has determined, based on a preplanned interim analysis, that continuation of the phase III PROSPECT study is futile.
- 14 Sep 2017 Status changed from active, no longer recruiting to discontinued, according to a Bavarian Nordic media release.
- 11 Sep 2017 According to a Bavarian Nordic media relaese, data will be presented at the ESMO 2017 Congress.